| Literature DB >> 27738363 |
Unax Lertxundi1, Saioa Domingo-Echaburu1, Javier Peral1, Montserrat García1.
Abstract
Published literature shows that dopamine agonists can reverse antipsychotic-induced hyperprolactinemia without worsening psychotic symptoms in the majority of schizophrenic patients. However, psychiatrists have been reluctant to use drugs with dopaminergic properties for fear of exacerbating psychiatric symptoms. There are reported cases of psychosis worsening published for both cabergoline and bromocriptine. Cabergoline has proven to be more effective and safe when used to treat hyperprolactinemia, but whether cabergoline is also safer than bromocriptine in antipsychotic induced hyperprolactinemia remains unproven.Entities:
Keywords: Antipsychotic; Bromocriptine; Cabergoline; Hyperprolactinemia; Pharmacovigilance
Year: 2011 PMID: 27738363 PMCID: PMC5044550
Source DB: PubMed Journal: Psychopharmacol Bull ISSN: 0048-5764